Stockreport

Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Recommendation supported by safety and efficacy results from several clinical studies and real-world evidence If approved, Rezurock would offer a new treatment option [Read more]